Who Paid My Doc
Outcomes Database to prospectivelY aSSEss changing TherapY landscape in Renal Cell Carcinoma (ODYSSEY RCC)
Research payments
$1,776,785
Through program year 2025, $1,776,785 in research payments was reported against Outcomes Database to prospectivelY aSSEss changing TherapY landscape in Renal Cell Carcinoma (ODYSSEY RCC), across 4 payments, paid by E.R. Squibb & Sons, L.L.C..
- Paid by
- E.R. Squibb & Sons, L.L.C.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $571,428 | 1 |
| 2024 | Research | $348,214 | 1 |
| 2023 | Research | $571,428 | 1 |
| 2022 | Research | $285,714 | 1 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
1 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.